Critical Earnings Report Looms for Sight Sciences

All eyes are on Sight Sciences as the company prepares to release its third-quarter 2025 financial results after market close this Thursday. This earnings announcement represents a pivotal moment for the ophthalmic-focused medical technology firm, with investors keen to assess whether recent operational challenges are being effectively addressed.

Market researchers project that Sight Sciences will report a loss of $0.26 per share for the July-September period. Revenue expectations center around $17.7 million. These figures will provide crucial context for evaluating the company’s trajectory following a disappointing second quarter.

In Q2, the company experienced an 8% decline in total revenue, which fell to $19.6 million. The Surgical Glaucoma segment was particularly affected, registering a 5% decrease. Read more...